ClinicalTrials.gg
CompletedNCT04145440M-PLACEUpdated Feb 24, 2025Results posted

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

A Phase 1/2 interventional study of MOR202 in Glomerulonephritis, Membranous and antiPLA2R Positive, sponsored by HI-Bio, A Biogen Company. Completed at 45 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by HI-Bio, A Biogen Company (part of Biogen) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Glomerulonephritis, Membranous with a site in United States — 13 open to participants now, 16 under way, 5 of them phase 3. Glomerulonephritis, Membranous · United States.

Enrollment
15th of 32
31 · median 31
Started
2019
the only one that year
Phase 1/2
3 of 35
none open now
Registered
20th of 35
by date

Among the 35 studies in Glomerulonephritis, Membranous with a site in United States, this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 1/2, and was the 20th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

13 of the 35 studies in Glomerulonephritis, Membranous with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Glomerulonephritis, Membranous with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)

Read the detailed description

After treatment subjects will be observed for up to 1 year.

Study Sponsor, originally HI-Bio, Inc., is now HI-Bio, A Biogen Company.

03

Conditions studied

  • Glomerulonephritis, Membranous
  • antiPLA2R Positive
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • > 18 to \< 80 years (at date of signing form [ICF]).
  • Urine protein to creatinine ratio (UPCR) of ≥ 3.000 g/g OR proteinuria ≥ 3.500 g/24 h from 24-h urine at screening
  • Active anti-PLA2R antibody positive MN in need of therapy (IST) according to investigator judgement and diagnosed on the basis of a , archival biopsy acquired within 5 years prior to screening is acceptable.
  • Estimated ≥ 50 ml/min/1.73m² or ≥ 30 and \<50 ml/min/1.73m², and interstitial fibrosis and tubular atrophy score of less than 25% on a renal biopsy obtained within the last 6 months prior to start of screening.
  • Not in spontaneous remission despite proper treatment with ACEIs, ARBs (sufficient dose and treatment duration) as per clinical practice and scientific guidelines. If the subject is intolerant to an ACEI or ARB, the reason must be documented and approval obtained prior to enrolment.
  • Systolic blood pressure BP ≤150 mmHg and diastolic BP ≤100 mmHg after 5 minutes of rest
  • Vaccinated against Pneumococcus within the last 5 years prior to date of signing informed consent (subjects may be vaccinated during screening to meet this criterion; interval to first dose of MOR202 must be at least 14 days).
  • Cohort 1 comprises newly diagnosed or subjects: Serum anti-PLA2R antibodies ≥50.0 RU/mL
  • Cohort 2 comprises therapy refractory subjects: a Subject did not achieve immunological remission after prior IST(s) as documented by the investigator AND b Subject is without promising standard therapeutic options as documented by the investigator (i.e. investigator expects efficacy or safety issues with remaining IST options) AND c Serum anti-PLA2R antibodies ≥ 20.0 RU/mL measured at screening

Note: France will only enroll patients in Cohort 2.

Key Exclusion Criteria:

  • \< 80 g/L.
  • Thrombocytopenia: \< 100.0 x 109/L.
  • Neutropenia: Neutrophils \< 1.5 x 109/L.
  • Leukopenia: Leukocytes \< 3.0 x 109/L.
  • Hypogammaglobulinemia: Serum immunoglobulins ≤ 4.0 g/L.

Subjects may receive supportive therapies to meet the above criteria

  • B-cells \< 5 x 106/L.
  • Secondary cause of MN (e.g. Systemic lupus erythematosus, medications, )
  • Concomitant renal disease other than MN (e.g., diabetic renal disease, lupus nephritis, IgA nephropathy).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Cohort 1 (newly diagnosed or relapsed participants)

    Participants with newly diagnosed or relapsed membranous nephropathy received MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occurred weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.

    Drug: MOR202

  • Experimental
    Cohort 2 (refractory participants)

    Participants with membranous nephropathy refractory to immunosuppressive treatment received MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occurred weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.

    Drug: MOR202

Interventions

  • DrugMOR202

    Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 1 to Week 24

  2. Percentage of Participants With Adverse Events

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 1 to Week 24

Secondary outcomes

  1. Best Immunological Response Rate (BIRR)

    The BIRR was defined as the percentage of participants with a best immunological response of stringent immunological complete response (sICR), immunological complete response (ICR), or immunological partial response (IPR) prior to the start of prohibited treatment or progression, based on reduction of serum anti-PLA2R antibody titer.

    Time frame: Up to 52 weeks

  2. Number of Participants Tested Positive for Anti-felzartamab Antibodies

    Time frame: Baseline; Up to 52 weeks

  3. Percentage of Participants Tested Positive for Anti-felzartamab Antibodies

    Time frame: Baseline; Up to 52 weeks

  4. Antibody Titers of Participants Tested Positive for Anti-felzartamab Antibodies

    Time frame: Baseline; Up to 52 weeks

  5. Felzartamab Serum Concentrations After Multiple Intravenous Administrations

    Time frame: Pre Dose and Post Dose on Cycle 1 Day 1 (C1D1), C1D8, C1D15, C1D22, C2D1, C3D1, C4D1, C5D1, C6D1, End of Treatment (week 24), Follow-up visit (week 38), End of Study (up to 52 weeks)

  6. Number of Participants With AEs During the Follow-up Period

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 25 to Week 52

  7. Percentage of Participants With AEs During the Follow-up Period

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 25 to Week 52

07

Results

Posted Dec 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Started1813
Received at least 1 dose of study drug1813
Completed1310
Not completed53
Withdrew: Physician decision30
Withdrew: Use of prohibited therapy23

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 1 to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Number of Participants With Adverse Events1512
PrimaryPercentage of Participants With Adverse Events

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 1 to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Percentage of Participants With Adverse Events83.392.3
SecondaryBest Immunological Response Rate (BIRR)

The BIRR was defined as the percentage of participants with a best immunological response of stringent immunological complete response (sICR), immunological complete response (ICR), or immunological partial response (IPR) prior to the start of prohibited treatment or progression, based on reduction of serum anti-PLA2R antibody titer.

Time frame:
Up to 52 weeks
Reported as:
Number · percentage of participants
Best Immunological Response Rate (BIRR)
percentage of participantsCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Best Immunological Response Rate (BIRR)83.3 (58.6 to 96.4)61.5 (31.6 to 86.1)
SecondaryNumber of Participants Tested Positive for Anti-felzartamab Antibodies
Time frame:
Baseline; Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants Tested Positive for Anti-felzartamab Antibodies
ParticipantsCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Baseline11
Post First Dose (52 weeks)10
SecondaryPercentage of Participants Tested Positive for Anti-felzartamab Antibodies
Time frame:
Baseline; Up to 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Tested Positive for Anti-felzartamab Antibodies
percentage of participantsCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Baseline6.77.7
Post First Dose (52 weeks)6.70.0
SecondaryAntibody Titers of Participants Tested Positive for Anti-felzartamab Antibodies
Time frame:
Baseline; Up to 52 weeks
Reported as:
Mean · anti-felzartamab antibody titers
Antibody Titers of Participants Tested Positive for Anti-felzartamab Antibodies
anti-felzartamab antibody titersCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Baseline13.10 ± NA11.50 ± NA
Post First Dose (52 weeks)3.48 ± NA—
SecondaryFelzartamab Serum Concentrations After Multiple Intravenous Administrations
Time frame:
Pre Dose and Post Dose on Cycle 1 Day 1 (C1D1), C1D8, C1D15, C1D22, C2D1, C3D1, C4D1, C5D1, C6D1, End of Treatment (week 24), Follow-up visit (week 38), End of Study (up to 52 weeks)
Reported as:
Geometric mean · nanogram(s)/millilitre (ng/mL)
Felzartamab Serum Concentrations After Multiple Intravenous Administrations
nanogram(s)/millilitre (ng/mL)Cohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Pre-dose C1D10.0 ± 0.00.0 ± 0.0
Post-dose C1D1323499.3 ± 98.3301417.5 ± 151.9
Pre-dose C1D889381.7 ± 97.9129924.9 ± 100.7
Post-dose C1D8425669.4 ± 50.7429629.4 ± 91.7
Pre-dose C1D15174658.7 ± 75.5189047.7 ± 80.9
Post-dose C1D15456390.9 ± 70.6547940.5 ± 60.2
Pre-dose C1D22185140.7 ± 78.0286607.9 ± 25.7
Post-dose C1D22495612.5 ± 57.3656862.8 ± 29.7
Pre-dose C2D124903.4 ± 47.3148097.2 ± 193.7
Post-dose C2D1474157.9 ± 108.0415814.9 ± 106.3
Pre-dose C3D134111.0 ± 164.725879.8 ± 572.2
Pre-dose C4D119811.2 ± 218.130655.9 ± 128.9
Pre-dose C5D127021.6 ± 152.035176.1 ± 84.1
Pre-dose C6D128734.6 ± 116.930383.0 ± 88.8
End of Treatment (week 24)12367.0 ± 349.933813.6 ± 61.9
Follow-up visit (week 38)369.0 ± NA—
End of Study (up to week 52)278.0 ± NA—
SecondaryNumber of Participants With AEs During the Follow-up Period

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 25 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With AEs During the Follow-up Period
ParticipantsCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Number of Participants With AEs During the Follow-up Period85
SecondaryPercentage of Participants With AEs During the Follow-up Period

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 25 to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With AEs During the Follow-up Period
percentage of participantsCohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)
Percentage of Participants With AEs During the Follow-up Period44.438.5

Adverse events

Collected over Week 1 to Week 52 (Weeks 1-24 [Treatment Period]; Weeks 25-52 [Follow-up Period]). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (Newly Diagnosed or Relapsed Participants) Treatment Period (Weeks 1-24)0/18 (0%)2/18 (11.1%)15/18 (83.3%)
Cohort 2 (Refractory Participants) Treatment Period (Weeks 1-24)0/13 (0%)3/13 (23.1%)12/13 (92.3%)
Cohort 1 (Newly Diagnosed or Relapsed Participants) Follow-up Period (Weeks 25-52)0/18 (0%)1/18 (5.6%)8/18 (44.4%)
Cohort 2 (Refractory Participants) Follow-up Period (Weeks 25-52)0/13 (0%)1/13 (7.7%)5/13 (38.5%)
Most frequent serious events
Most frequent serious events
EventCohort 1 (Newly Diagnosed or Relapsed Participants) Treatment Period (Weeks 1-24)Cohort 2 (Refractory Participants) Treatment Period (Weeks 1-24)Cohort 1 (Newly Diagnosed or Relapsed Participants) Follow-up Period (Weeks 25-52)Cohort 2 (Refractory Participants) Follow-up Period (Weeks 25-52)
Foot fractureInjury, poisoning and procedural complications0/181/130/180/13
NeutropeniaBlood and lymphatic system disorders0/181/130/180/13
Type I hypersensitivityImmune system disorders0/181/130/180/13
GoutMetabolism and nutrition disorders0/180/130/181/13
Infusion related reactionInjury, poisoning and procedural complications1/180/130/180/13
Cerebrovascular accidentNervous system disorders0/180/131/180/13
COVID-19Infections and infestations1/180/130/180/13
Most frequent other events
Showing 10 of 99
Most frequent other events
EventCohort 1 (Newly Diagnosed or Relapsed Participants) Treatment Period (Weeks 1-24)Cohort 2 (Refractory Participants) Treatment Period (Weeks 1-24)Cohort 1 (Newly Diagnosed or Relapsed Participants) Follow-up Period (Weeks 25-52)Cohort 2 (Refractory Participants) Follow-up Period (Weeks 25-52)
Infusion related reactionInjury, poisoning and procedural complications0/188/130/180/13
HypogammaglobulinaemiaImmune system disorders7/181/131/180/13
Oedema peripheralGeneral disorders2/184/130/181/13
BronchitisInfections and infestations0/184/131/180/13
NauseaGastrointestinal disorders4/181/130/180/13
Lipase increasedInvestigations3/180/131/180/13
HeadacheNervous system disorders3/180/130/180/13
ArthralgiaMusculoskeletal and connective tissue disorders3/180/131/180/13
Chest painGeneral disorders1/182/131/180/13
PyrexiaGeneral disorders0/182/130/180/13

Baseline characteristics

The Full Analysis Set (FAS) included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)Total
Mean59.2 ± 11.3455.0 ± 12.4757.5 ± 11.81
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)Total
Female527
Male131124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)Total
Hispanic or Latino224
Not Hispanic or Latino16824
Unknown or Not Reported033
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (Newly Diagnosed or Relapsed Participants)Cohort 2 (Refractory Participants)Total
American Indian or Alaska Native101
Asian404
Native Hawaiian or Other Pacific Islander000
Black or African American011
White13821
More than one race000
Unknown or Not Reported044
08

Study locations

45 sites
  • North America Research Institute
    Azusa, California 91702, United States
  • UCSF Medical Center
    San Francisco, California 94143, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • University of Miami Division of Nephrology & Hypertension
    Miami, Florida 33136, United States
  • GA Nephrology Associates
    Lawrenceville, Georgia 30046, United States
  • Northwest Louisiana Nephrology Research
    Shreveport, Louisiana 71101, United States
  • Kidney Care and Transplant Services of New England, PC
    Springfield, Massachusetts 01107, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • MedResearch, Inc
    El Paso, Texas 79905, United States
  • Texas Research Institute
    Fort Worth, Texas 76248, United States
  • St. George Hospital
    Sydney, New South Wales 2217, Australia
  • Royal Melbourne Hospital
    Melbourne, Victoria 3050, Australia
  • Western Health
    Melbourne, 3021, Australia
  • O.L.V. Ziekenhuis
    Aalst, 9300, Belgium
  • C.H.U. Brugmann - Site Victor Horta
    Brussels, 1020, Belgium
  • Universitair Ziekenhuis Brussels
    Brussels, 1090, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • Groupe Hospitalier Pellegrin - Hôpital Pellegrin
    Bordeaux, 33000, France
  • CHU de Grenoble - Hôpital Albert Michallon
    Grenoble, 38043, France
  • Hopital Claude Huriez -CHU Lille
    Lille, 59037, France
  • Hopital Tenon Service de nephrologie
    Paris, 75020, France
  • CHU Saint Etienne - Hôpital Nord
    Saint-Priest-en-Jarez, 42055, France
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, 50134, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Ospedale Borgo Roma
    Verona, 37124, Italy
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Hallym University Kangdong Sacred Heart Hospital
    Seoul, 05355, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, 06273, Korea, Republic of
  • The Catholic University of Korea
    Seoul, 06591, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, Korea, Republic of
  • Radboud UMC Niimegen Nephrology
    Nijmegen, 6525 GA, Netherlands
  • Centrum Zdrowia MDM
    Warsaw, 00631, Poland
  • Miedzyleski Szpital Specjalistyczny
    Warsaw, 04749, Poland
  • SPZOZ Centralny Szpital Kliniczny UM w Lodzi
    Łódź, 92213, Poland
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 8035, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 50134, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, 28222, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • Hospital Universitario Dr. Peset
    Valencia, 46017, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Jan 2022, 27 months.

Results were first posted in Dec 2024, 2 years 11 months after primary completion. A results delay was requested in Nov 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2019
First posted
Oct 30, 2019
StartActual
Oct 15, 2019
Primary completionActual
Jan 19, 2022
CompletionActual
Aug 2, 2022
Results delay requested
Nov 21, 2022
Results first posted
Dec 24, 2024
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04145440
Responsible party
Sponsor
First posted
Oct 30, 2019
Start date
Oct 15, 2019
Primary completion
Jan 19, 2022
Completion
Aug 2, 2022
Results posted
Dec 24, 2024
Last update
Feb 24, 2025

Study contacts

Medical Director
study director · HI-Bio, A Biogen Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion